{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:06:09Z","timestamp":1793160369599,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00296-021-04945-w","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T18:09:50Z","timestamp":1626286190000},"page":"1403-1409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-183X","authenticated-orcid":false,"given":"Sadao","family":"Jinno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5289-139X","authenticated-orcid":false,"given":"Kengo","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-1273","authenticated-orcid":false,"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-9246","authenticated-orcid":false,"given":"Yoko","family":"Nose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-6584","authenticated-orcid":false,"given":"Mai","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-3743","authenticated-orcid":false,"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"4945_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1086\/314893","volume":"180","author":"C Chan","year":"1999","unstructured":"Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180:369\u2013376","journal-title":"J Infect Dis"},{"key":"4945_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","volume":"24","author":"C Colby","year":"1999","unstructured":"Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/sulfamethoxazole as pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24:897\u2013902. https:\/\/doi.org\/10.1038\/sj.bmt.1702004","journal-title":"Bone Marrow Transplant"},{"key":"4945_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1345\/aph.17464","volume":"32","author":"CD Freeman","year":"1998","unstructured":"Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH (1998) Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 32:1004\u20131007. https:\/\/doi.org\/10.1345\/aph.17464","journal-title":"Ann Pharmacother"},{"key":"4945_CR4","doi-asserted-by":"publisher","first-page":"E184","DOI":"10.1111\/j.1399-0012.2012.01624.x","volume":"26","author":"S Gabardi","year":"2012","unstructured":"Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A (2012) Atovaquone versus trimethoprim-sulfamethoxazole as pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant 26:E184\u2013E190. https:\/\/doi.org\/10.1111\/j.1399-0012.2012.01624.x","journal-title":"Clin Transplant"},{"key":"4945_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00296-007-0505-4","volume":"28","author":"M Kimura","year":"2008","unstructured":"Kimura M, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H (2008) Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int 28:673\u2013676. https:\/\/doi.org\/10.1007\/s00296-007-0505-4","journal-title":"Rheumatol Int"},{"key":"4945_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","volume":"25","author":"T Kitazawa","year":"2019","unstructured":"Kitazawa T, Seo K, Yoshino Y, Asako K, Kikuchi H, Kono H et al (2019) Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother 25:351\u2013354","journal-title":"J Infect Chemother"},{"key":"4945_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67\u201376. https:\/\/doi.org\/10.1080\/03602530902722679","journal-title":"Drug Metab Rev"},{"key":"4945_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00296-008-0721-6","volume":"29","author":"R Lertnawapan","year":"2009","unstructured":"Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S (2009) Risk factors of pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 29:491\u2013496. https:\/\/doi.org\/10.1007\/s00296-008-0721-6","journal-title":"Rheumatol Int"},{"key":"4945_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","volume":"183","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A et al (2011) An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96\u2013128. https:\/\/doi.org\/10.1164\/rccm.2008-740ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4945_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77:644\u2013649. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211796","journal-title":"Ann Rheum Dis"},{"key":"4945_CR11","first-page":"480","volume":"30","author":"J Pope","year":"2003","unstructured":"Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J (2003) Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 30:480\u2013484","journal-title":"J Rheumatol"},{"key":"4945_CR12","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1086\/383150","volume":"38","author":"M Rodriguez","year":"2004","unstructured":"Rodriguez M, Sifri CD, Fishman JA (2004) Failure of low-dose atovaquone prophylaxis against pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 38:e76\u2013e78. https:\/\/doi.org\/10.1086\/383150","journal-title":"Clin Infect Dis"},{"key":"4945_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cir335","volume":"53","author":"PE Sax","year":"2011","unstructured":"Sax PE, Komarow L, Finkelman MA, Grant PM, Andersen J, Scully E et al (2011) Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related pneumocystis jirovecii pneumonia. Clin Infect Dis 53:197\u2013202. https:\/\/doi.org\/10.1093\/cid\/cir335","journal-title":"Clin Infect Dis"},{"key":"4945_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4065\/74.7.730","volume":"74","author":"JD Smilack","year":"1999","unstructured":"Smilack JD (1999) Trimethoprim-sulfamethoxazole. Mayo Clin Proc 74:730\u2013734","journal-title":"Mayo Clin Proc"},{"key":"4945_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s10165-012-0730-x","volume":"23","author":"K Takenaka","year":"2013","unstructured":"Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K (2013) A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol 23:752\u2013758. https:\/\/doi.org\/10.1007\/s10165-012-0730-x","journal-title":"Mod Rheumatol"},{"key":"4945_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","volume":"19","author":"M Utsunomiya","year":"2017","unstructured":"Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K et al (2017) Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19:7\u2013016. https:\/\/doi.org\/10.1186\/s13075-016-1206-8","journal-title":"Arthritis Res Ther"},{"key":"4945_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","volume":"41","author":"P Vananuvat","year":"2011","unstructured":"Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S (2011) Primary prophylaxis for pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41:497\u2013502. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.004","journal-title":"Semin Arthritis Rheum"},{"key":"4945_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002685","volume":"15","author":"M Warny","year":"2018","unstructured":"Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE (2018) Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 15:e1002685. https:\/\/doi.org\/10.1371\/journal.pmed.1002685","journal-title":"PLoS Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04945-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T04:08:23Z","timestamp":1657858103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04945-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4945"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04945-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have declared no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This observational study was conducted as per the Declaration of Helsinki. The study was approved by the ethics committee of Kobe University (approval number B190296). In our institute, the institutional review board waived the requirement for patients\u2019 informed consent, because this study utilized only existing data collected in clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}